Algernon Pharmaceuticals, Inc. (AGN) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.5 k

Shareholding (May 2023)

FII

0.06%

Held by 1 FIIs

DII

99.94%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 2 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.05

Return on Equity

-100.94%

Price to Book

1.33

Revenue and Profits:

Net Sales:

(Quarterly Results - May 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

14.29%

6 Months

6.67%

1 Year

0.0%

2 Years

0.0%

3 Years

-85.08%

4 Years

-90.52%

5 Years

-99.05%

Algernon Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

11.43%

EBIT to Interest (avg)

-5.58

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.07

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.06%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.18

EV to EBIT

-1.11

EV to EBITDA

-1.13

EV to Capital Employed

1.19

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-106.28%

ROE (Latest)

-100.94%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : May 2023

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - May'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended May 2025 is 0.00% vs 0.00% in May 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended May 2025 is -142.86% vs 227.27% in May 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "May'25",
        "May'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.60",
          "val2": "-0.50",
          "chgp": "-20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.60",
          "val2": "1.40",
          "chgp": "-142.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Aug'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Aug 2024 is 0.00% vs 0.00% in Aug 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Aug 2024 is 92.65% vs -11.48% in Aug 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Aug'24",
        "Aug'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.40",
          "val2": "-5.20",
          "chgp": "53.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "-1.50",
          "chgp": "113.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.50",
          "val2": "-6.80",
          "chgp": "92.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - May'25 - YoY

May'25

May'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.60

-0.50

-20.00%

Interest

0.00

Exceptional Items

0.00

0.20

-100.00%

Consolidate Net Profit

-0.60

1.40

-142.86%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended May 2025 is 0.00% vs 0.00% in May 2024

Consolidated Net Profit

YoY Growth in quarter ended May 2025 is -142.86% vs 227.27% in May 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Aug'24

Aug'24

Aug'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.40

-5.20

53.85%

Interest

0.00

Exceptional Items

0.20

-1.50

113.33%

Consolidate Net Profit

-0.50

-6.80

92.65%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Aug 2024 is 0.00% vs 0.00% in Aug 2023

Consolidated Net Profit

YoY Growth in year ended Aug 2024 is 92.65% vs -11.48% in Aug 2023

All Annual Results

Company CV

About Algernon Pharmaceuticals, Inc.

Algernon Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Algernon Pharmaceuticals Inc, formerly Breathtec Biomedical Inc, is a Canada-based drug development company. The Company is focused on the areas of nonalcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). The Company’s drug discovery approach is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.

Company Coordinates

Company Details

700 Pender St W Suite 915 , VANCOUVER BC : V6C 1G8

Tel: 1 604 6461553

https://algernonpharmaceuticals.com

Registrar Details